Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral MP1032 in moderate-to-severe chronic plaque psoriasis
2017-003484-36Phase 2Completed
- Sponsor
- MetrioPharm AG
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mp1032 in psoriasis and plaque psoriasis (3 arms), sponsored by MetrioPharm AG. Primary endpoint: Psoriasis Area and Severity Index comparison. Started Sep 2017; status: completed.
02
Drugs
mp1032
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2017-003484-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003484-36.